APA (7th ed.) Citation

Allaf, M., Kim, S., Harshman, L., McDermott, D., Master, V., Signoretti, S., . . . Haas, N. (2022). LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. Annals of Oncology, 33, S1432. https://doi.org/10.1016/j.annonc.2022.08.072

Chicago Style (17th ed.) Citation

Allaf, M., et al. "LBA67 Phase III Randomized Study Comparing Perioperative Nivolumab (nivo) Versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network Trial." Annals of Oncology 33 (2022): S1432. https://doi.org/10.1016/j.annonc.2022.08.072.

MLA (9th ed.) Citation

Allaf, M., et al. "LBA67 Phase III Randomized Study Comparing Perioperative Nivolumab (nivo) Versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network Trial." Annals of Oncology, vol. 33, 2022, p. S1432, https://doi.org/10.1016/j.annonc.2022.08.072.